SCHEMBL10332010

SCHEMBL10332010

CCc1ccc(-c2ccc(C(=O)N3CCC(F)(F)CC3)cc2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ SLC6A7 Q99884 3/20 0.44
▸ GRIN2B Q13224 4/20 0.42
▸ TSHR P16473 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ JAK3 P52333 1/20 0.40
▸ P2RY12 Q9H244 1/20 0.39
▸ LIPC P11150 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ ABL1 P00519 2/20 0.38
▸ BCR P11274 2/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP2D6 P10635 1/20 0.37
▸ MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10331953 0.93 GRIN2B (0.46) ALDH1A1HPGDSLC6A7GRIN2BTSHR
SCHEMBL10331954 0.86 HPGD (0.61) ALDH1A1HPGDSLC6A7GRIN2BTSHR
SCHEMBL10331961 0.86 ALDH1A1 (0.57) ALDH1A1HPGDSLC6A7GRIN2BMEN1
SCHEMBL14154450 0.84 PHGDH (0.51) ALDH1A1HPGDSLC6A7HTTLMNA
SCHEMBL14207505 0.84 SLC6A7 (0.61) ALDH1A1HPGDSLC6A7GRIN2BJAK2
SCHEMBL10331366 0.83 SLC6A7 (0.46) ALDH1A1HPGDSLC6A7MEN1KMT2A
SCHEMBL7902733 0.77 SLC6A7 (0.51) ALDH1A1HPGDSLC6A7MEN1KMT2A
SCHEMBL10331356 0.76 NAMPT (0.47) ALDH1A1HPGDSLC6A7MEN1KMT2A
SCHEMBL19753619 0.75 P2RY12 (0.40) KMT2AP2RY12LIPC
SCHEMBL20772483 0.73 HSD11B1 (0.40) ALDH1A1MEN1KMT2AHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222247-B2 Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2012-07-17 — — US disclosed
US-20100004219-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2010-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004219-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF NR3C1, NFRKB, RELA ALDH1A1 4091/4885HPGD 3552/4885SLC6A7 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback